Lenabasum for Diffuse Cutaneous Systemic Sclerosis

Despite a short trial duration in a small number of patients, this phase 2 study in dcSSc found that lenabasum improves outcomes and underlying disease pathology, with a favorable safety profile.

Refer to the full study for all source material.

Excerpted and adapted from:

Spiera R, Hummers L, Chung L, et al. Safety and efficacy of lenabasum in a phase II, randomized, placebo-controlled trial in adults with systemic sclerosis. Arthritis Rheumatol. 2020 Aug;72(8):1350–1360.